

*

NET SALES AS OF MARCH 31, 2019

Longjumeau, April, 24th 2019

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its net sales as of March, 31st 2019.

The PCAS Group had generated consolidated net sales of €50.6 million as of March, 31st 2019, representing an increase of 9.2% compared to the same period during the previous financial year (+7.4% at a constant exchange rate).

<i>in millions of euros</i>	2019	2018	Growth in %	2019 At constant exchange rates	Growth in %
Net sales as of March 31st	50,6	46,4	9,2%	49,8	7,4%
<i>.Pharmaceutical Synthesis</i>	<i>29,9</i>	<i>27,8</i>	<i>7,6%</i>	<i>29,3</i>	<i>5,4%</i>
<i>Fine Specialty Chemicals</i>	<i>20,8</i>	<i>18,6</i>	<i>11,7%</i>	<i>20,5</i>	<i>10,5%</i>

Pharmaceutical Synthesis

The Pharmaceutical Synthesis business in Health generated €29.9 million, up 7.6% on 2018 which was a relatively low base (+5.4% at a constant exchange rate). Operational difficulties continued throughout the quarter, especially at one of our Pharmaceutical production sites, which were compounded by supply failures of certain raw materials, all of which still producing an adverse effect on business levels.

Fine Specialty Chemicals

Net sales of Fine Specialty Chemicals totaled €20.8 million, up 11.7% on 2018 (+10.5% at a constant exchange rate), with growth across all markets, particularly in Cosmetics and Electronics. Several new industrialization projects were also launched during the same period.

Outlook for the current year

In 2019, the Group's net sales are expected to show modest growth despite operational difficulties that continued during the first quarter in Pharmaceuticals, which make it difficult to anticipate trends in the Group's results to date.



NEXT FINANCIAL DISCLOSURE:

Net sales for the 1st half of 2019, July, 24th 2019

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 9% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €206.7 million in 2018 and employs close to 1 100 people in six countries.

To find out more about PCAS, visit: www.pcas.com

PCAS

Newcap



Frédéric Desdouits / Eric Moissenot

PCAS

Tel. : +33 1 69 79 61 32
www.pcas.com

Emmanuel Huynh / Louis-Victor Delouvrier

NewCap

Financial Communication & Investor Relations

Tel. : +33 1 44 71 98 53
pcas@newcap.eu